The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
3-amino-2-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)benzyl)-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-methylpropanamide ID: ALA1091852
PubChem CID: 15981185
Max Phase: Preclinical
Molecular Formula: C30H31Cl3F2N2O2
Molecular Weight: 595.95
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CC(CN)(Cc1ccc(CCCOc2c(F)ccc(F)c2Cl)cc1)C(=O)N(Cc1cccc(Cl)c1Cl)C1CC1
Standard InChI: InChI=1S/C30H31Cl3F2N2O2/c1-30(18-36,29(38)37(22-11-12-22)17-21-5-2-6-23(31)26(21)32)16-20-9-7-19(8-10-20)4-3-15-39-28-25(35)14-13-24(34)27(28)33/h2,5-10,13-14,22H,3-4,11-12,15-18,36H2,1H3
Standard InChI Key: KBBHXCQPIMWCBS-UHFFFAOYSA-N
Molfile:
RDKit 2D
39 42 0 0 0 0 0 0 0 0999 V2000
-3.3933 -16.0875 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.3945 -16.9150 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6770 -17.3280 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9622 -16.9146 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9654 -16.0834 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6789 -15.6747 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6817 -14.8497 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9704 -14.4349 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2519 -14.8496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.5406 -14.4347 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.1779 -14.8448 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1784 -15.6671 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8914 -16.0770 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6037 -15.6622 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.5981 -14.8325 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8844 -14.4265 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8774 -13.6016 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
2.3123 -14.4148 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-0.5380 -16.0808 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-2.6772 -18.1530 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9647 -18.5657 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9649 -19.3907 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2478 -19.8034 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.2474 -18.1534 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.5349 -18.5660 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.2472 -17.3284 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.5351 -19.3910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1778 -18.1537 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8947 -18.5665 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8904 -19.3887 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6020 -19.8013 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3203 -19.3889 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3177 -18.5592 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6009 -18.1508 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.5963 -17.3258 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
3.0287 -18.1488 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
-0.9439 -20.1091 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1189 -20.1093 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6812 -18.9704 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12 19 1 0
4 5 1 0
3 20 1 0
9 10 1 0
20 21 1 0
2 3 1 0
21 22 1 0
10 11 1 0
22 23 1 0
5 6 2 0
21 24 1 0
11 12 2 0
24 25 1 0
6 1 1 0
24 26 2 0
12 13 1 0
25 27 1 0
1 2 2 0
25 28 1 0
13 14 2 0
28 29 1 0
6 7 1 0
29 30 2 0
14 15 1 0
30 31 1 0
3 4 2 0
31 32 2 0
15 16 2 0
32 33 1 0
16 11 1 0
33 34 2 0
34 29 1 0
7 8 1 0
34 35 1 0
16 17 1 0
33 36 1 0
37 27 1 0
38 37 1 0
27 38 1 0
15 18 1 0
8 9 1 0
21 39 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 595.95Molecular Weight (Monoisotopic): 594.1419AlogP: 7.64#Rotatable Bonds: 12Polar Surface Area: 55.56Molecular Species: BASEHBA: 3HBD: 1#RO5 Violations: 2HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 9.01CX LogP: 7.99CX LogD: 6.39Aromatic Rings: 3Heavy Atoms: 39QED Weighted: 0.17Np Likeness Score: -0.91
References 1. Chen A, Bayly C, Bezençon O, Richard-Bildstein S, Dubé D, Dubé L, Gagné S, Gallant M, Gaudreault M, Grimm E, Houle R, Lacombe P, Laliberté S, Lévesque JF, Liu S, MacDonald D, Mackay B, Martin D, McKay D, Powell D, Remen L, Soisson S, Toulmond S.. (2010) Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension., 20 (7): [PMID:20206513 ] [10.1016/j.bmcl.2010.02.036 ]